Abstract
Adenoviruses (Ads) are arguably one of the most potent viruses for in vivo gene therapy, vaccine, and oncolytic applications. The attraction for the use of Ads stems from their ability to infect a wide range of dividing and non-dividing cell types in some cases to efficiencies of nearly 100%. Additional benefits include their stability, the ability to purify the vector to concentrations of up to 1013 particles/ml, and the fact that viral vectors self-assemble into particles of specific size (~100 nm). The vast majority of clinical applications of Ad have utilized Ad serotype 5 (Ad5) viruses. Considering that at least half of humans are already immune to Ad5, Ad5 oncolytics may not be optimal for clinical translation. Given this and that there are 54 different serotypes of human Ads, this review considers the utility of "mining" these alternate Ad serotypes for viruses that can evade Ad5 immunity and kill different types of cancer.
Keywords: Adenovirus, oncolytic, cancer, serotypes, liver damage, immunevasion, in vivo gene therapy, vector, serotypes
Current Pharmaceutical Biotechnology
Title:Mining the Adenovirus "Virome" for Systemic Oncolytics
Volume: 13 Issue: 9
Author(s): Michael A. Barry, Eric A. Weaver and Christopher Y. Chen
Affiliation:
Keywords: Adenovirus, oncolytic, cancer, serotypes, liver damage, immunevasion, in vivo gene therapy, vector, serotypes
Abstract: Adenoviruses (Ads) are arguably one of the most potent viruses for in vivo gene therapy, vaccine, and oncolytic applications. The attraction for the use of Ads stems from their ability to infect a wide range of dividing and non-dividing cell types in some cases to efficiencies of nearly 100%. Additional benefits include their stability, the ability to purify the vector to concentrations of up to 1013 particles/ml, and the fact that viral vectors self-assemble into particles of specific size (~100 nm). The vast majority of clinical applications of Ad have utilized Ad serotype 5 (Ad5) viruses. Considering that at least half of humans are already immune to Ad5, Ad5 oncolytics may not be optimal for clinical translation. Given this and that there are 54 different serotypes of human Ads, this review considers the utility of "mining" these alternate Ad serotypes for viruses that can evade Ad5 immunity and kill different types of cancer.
Export Options
About this article
Cite this article as:
A. Barry Michael, A. Weaver Eric and Y. Chen Christopher, Mining the Adenovirus "Virome" for Systemic Oncolytics, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958823
DOI https://dx.doi.org/10.2174/138920112800958823 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances
Current Drug Targets Viral Reservoirs an Impediment to HAART: New Strategies to Eliminate HIV-1
Current Drug Targets - Infectious Disorders Editorial [Hot Topic:Cervical Cancer - Current Challenges(Guest Editor: Adeola Olaitan)]
Current Women`s Health Reviews Betulinic Acid and Brosimine B Hybrid Derivatives as Potential Agents against Female Cancers
Anti-Cancer Agents in Medicinal Chemistry Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry HPV Cervical Infection and Immunodysregulation: Synergistic Risks for Neoplasia-Review
Current Women`s Health Reviews Recent Advances of Metal Binding Protein Lactoferrin as an Anti- Microbial Agent
Current Bioactive Compounds Integrated Therapeutic Approaches in Head and Neck Cancer: The Importance of Multidisciplinary Team Management
Anti-Cancer Agents in Medicinal Chemistry Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Nanocrystals as Effective Delivery Systems of Poorly Water-soluble Natural Molecules
Current Medicinal Chemistry Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes
Current Neurovascular Research Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Psychological Adjustment of Women in Cervical Cancer Screening
Current Women`s Health Reviews Polyphenols and Aging
Current Aging Science Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry